- Smilow Cancer Hospital Thoracic Oncology ProgramSmilow Cancer Hospital at North Haven6 Devine Street, Fl 2North Haven, CT 06473
- Smilow Cancer Hospital Phase I Unit55 Park StreetFl 1New Haven, CT 06511
So Yeon Kim, MD
Biography
So Yeon Kim, MD, is a medical oncologist who cares for patients with lung cancer, an area that she says is changing rapidly, thanks to new drugs in the past decade, targeted treatments, and immunotherapies that have led to significant improvements in outcomes even in people with advanced forms of the disease.
“I always knew I wanted to do something to help people,” Dr. Kim says. “I ultimately chose oncology because I enjoyed the long-term relationships I was able to build with patients and families. I really enjoy working with cancer patients because they are among the most resilient and courageous people, who continue to fight against a disease that still has many more problems to solve.”
Dr. Kim is working with colleagues toward personalizing cancer treatment for all patients with carefully selected treatment options based on the tumor’s “molecular fingerprint,” she says. “At Yale, there is a lot of ongoing scientific collaboration between clinicians and researchers that is helping bring the latest scientific discoveries to patients with the goal of improving their outcomes.”
An assistant professor at Yale School of Medicine, Dr. Kim focuses her research on both targeted treatment options and immunotherapy. “Oncology is a humbling field that can bring up more questions than answers, but I think that ultimately allows space for creativity and innovation,” she says. “While my research interests currently remain broad, I am interested in developing a more personalized approach to lung cancer care as we learn more about the science around what drives specific patients to respond better to certain therapies than to others,” she says.
Titles
- Assistant Professor
Education & Training
- MDAlbert Einstein College of Medicine (2016)
- ABPrinceton University (2011)
Additional Information
- ASCO Conquer Cancer Merit Award: ASCO (2022)
- Boiarsky D, Hong L, Ricciuti B, Cooper A, Saad M, Elkrief A, Di Federico A, Aminu M, Rinsurongkawong W, Le X, Luo J, Wu J, Gibbons D, Heymach J, Skoulidis F, Kim S, Schoenfeld A, Awad M, Zhang J, Vokes N. Disentangling KEAP1 and STK11 in KRAS-mutant (KRASm) non–small cell lung cancer (NSCLC) treated with immunotherapy. Journal Of Clinical Oncology 2026, 44: e20583-e20583. DOI: 10.1200/jco.2026.44.16_suppl.e20583.
- Boiarsky D, Hong L, Ricciuti B, Cooper A, Saad M, Elkrief A, Di Federico A, Aminu M, Rinsurongkawong W, Le X, Luo J, Wu J, Gibbons D, Heymach J, Skoulidis F, Kim S, Schoenfeld A, Awad M, Zhang J, Vokes N. Machine learning to identify biomarkers of response to immunotherapy in KRAS wildtype (KRASwt) non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2026, 44: e20609-e20609. DOI: 10.1200/jco.2026.44.16_suppl.e20609.
- Murciano-Goroff Y, Hollebecque A, Heist R, Cassier P, Han J, Kim S, Sabari J, Tosi D, Sacher A, Burns T, Shimizu T, Reddy Ammakkanavar N, Spira A, Gomez-Roca C, Patnaik A, Cosman R, Bodor J, Nagasaka M, You A, McNeely S, Peter R, Fink A, Chen A, Oxnard G, Willard M, Kuboki Y, Koyama T. Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study. Nature Communications 2026, 17: 3834. PMID: 41820335, PMCID: PMC13121619, DOI: 10.1038/s41467-026-69943-7.
- Gong G, Liu J, Pandya S, Taborda C, Wiesendanger N, Price N, Byron W, Coppi A, Young P, Wiess C, Dunning H, Barganier C, Brodeur R, Fischbach N, LoRusso P, Pusztai L, Kim S, Rozenblit M, Cecchini M, Mongiu A, Mendez L, Kaftan E, Torre C, Krumholz H, Krop I, Schulz W, Lustberg M, Kunz P. Clinical Trial Patient Matching: A Real-Time, Common Data Model and Artificial Intelligence–Driven System for Semiautomated Patient Prescreening in Cancer Clinical Trials. JCO Clinical Cancer Informatics 2026, 10: e2500262. PMID: 41512229, DOI: 10.1200/cci-25-00262.
- Cortellini A, Garbo E, La Cava G, Citarella F, Santo V, Brunetti L, Pinato D, Naidoo J, Loza M, Genova C, Gettinger S, Kim S, Jayakrishnan R, Zarif T, Russano M, Pecci F, Di Federico A, Montrone M, Owen D, Signorelli D, Li M, Camerini A, Halmos B, Vincenzi B, Metro G, Yendamuri S, Grossi F, Josephides E, Tomasik B, Giusti R, Bria E, Sebastian M, Rost M, Acker F, Landi L, Mazzoni F, Morabito A, Leonetti A, Cantini L, Mountzios G, Kalvapudi S, O'Reilly D, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Majem M, Piedra A, Cortinovis D, Tonini G, Minuti G, Mezquita L, Gorria T, Beninato T, Lo Russo G, PrelaJ A, De Giglio A, Biello F, Nana F, Dingemans A, Aerts J, Ferrara R, Abu Hejleh T, Takada K, Naqash A, Garassino M, Wakelee H, Nassar A, Ricciuti B, Soda P, Caruso C, Guarrasi V. Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity. Lung Cancer 2025, 209: 108799. PMID: 41108882, DOI: 10.1016/j.lungcan.2025.108799.
- Cortellini A, Santo V, Brunetti L, Garbo E, Pinato D, La Cava G, Naidoo J, Katz A, Loza M, Neal J, Genova C, Gettinger S, Kim S, Jayakrishnan R, Zarif T, Russano M, Pecci F, Di Federico A, Alessi J, Montrone M, Owen D, Ramella S, Signorelli D, Fidler M, Li M, Camerini A, Halmos B, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, D’Alessio A, Banna G, Fulgenzi C, Grisanti S, Grossi F, D’Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Balachandran K, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzoni F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Sforza V, Tiseo M, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Rocco D, Della Gravara L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O’Reilly D, Fitzpatrick O, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Piedra A, Agustoni F, Cortinovis D, Tonini G, Minuti G, Bennati C, Mezquita L, Gorría T, Servetto A, Beninato T, Russo G, Prelaj A, De Giglio A, Rogado J, Moliner L, Nadal E, Biello F, Nana F, Dingemans A, Aerts J, Ferrara R, Abu Hejleh T, Takada K, Naqash A, Garassino M, Peters S, Wakelee H, Nassar A, Ricciuti B, Soda P, Caruso C, Guarrasi V. Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry. Journal For ImmunoTherapy Of Cancer 2025, 13: e012423. PMID: 41022528, PMCID: PMC12481261, DOI: 10.1136/jitc-2025-012423.
- Kim S, Politi K, Goldberg S. Lasering in on Uncommon EGFR Mutations. Journal Of Thoracic Oncology 2025, 20: 1148-1151. PMID: 40914593, DOI: 10.1016/j.jtho.2025.06.014.
- Frisch A, Martin E, Kim S, Riess J, Sen T, Karim N. KRAS mutated NSCLC: past, present, and future directions in a rapidly evolving landscape. The Oncologist 2025, 30: oyaf153. PMID: 40586765, PMCID: PMC12207871, DOI: 10.1093/oncolo/oyaf153.
- Kim S, Park H, Chiang A. Small Cell Lung Cancer. JAMA: The Journal Of The American Medical Association 2025, 333: 1906-1917. PMID: 40163214, DOI: 10.1001/jama.2025.0560.
- Ayoade O, Canavan M, Zolfaghari E, Caturegli G, Kim S, Boffa D. Erratum to ‘Recent Survival Gains in Stage IV NSCLC by Sociodemographic Strata’ [JTO Clinical and Research Reports Volume 6 Issue 4 (2025) 100798]. JTO Clinical And Research Reports 2025, 6: 100850. PMID: 41473839, PMCID: PMC12745935, DOI: 10.1016/j.jtocrr.2025.100850.
- Fletcher K, Machaalani M, Chehade R, Nassar A, Nawfal R, Manos M, Menzies A, Aboubakar-Nana F, Hassel J, Pinato D, Johnson A, Olsson-Brown A, Carlino M, Malgeri A, Cortellini A, Singh A, Parikh K, Kim S, Naqash A, Long G, Challa P, Choueiri T, Sharon E, Shah S, Johnson D. Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic Disorders. JAMA Network Open 2025, 8: e2513727. PMID: 40465294, PMCID: PMC12138719, DOI: 10.1001/jamanetworkopen.2025.13727.
- Cortiula F, Kutiel T, Hsu M, Hendriks L, Nassar A, Moskovitz M, Kim S, Mirsky M, Jayakrishnan R, Bortolot M, Saddi J, Borghetti P, Chung M, Filippi A, De Ruysscher D, Bar J. Comparative efficacy of immunotherapy-based treatment versus chemotherapy-only in patients with unresectable NSCLC with disease progression post chemoradiation and durvalumab. European Journal Of Cancer 2025, 219: 115302. PMID: 39987799, DOI: 10.1016/j.ejca.2025.115302.
- Cortellini A, Brunetti L, Di Fazio G, Garbo E, Pinato D, Naidoo J, Katz A, Loza M, Neal J, Genova C, Gettinger S, Kim S, Jayakrishnan R, Zarif T, Russano M, Pecci F, Di Federico A, Awad M, Alessi J, Montrone M, Owen D, Signorelli D, Fidler M, Li M, Camerini A, De Giglio A, Young L, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, Awosika N, Napolitano A, Fulgenzi C, Grisanti S, Grossi F, D’Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Newsom-Davis T, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzoni F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Pantano F, Morabito A, Leonetti A, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Della Gravara L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O’Reilly D, Bell J, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Majem M, Agustoni F, Cortinovis D, Tonini G, Minuti G, Bennati C, Mezquita L, Gorría T, Servetto A, Beninato T, Russo G, Rogado J, Moliner L, Biello F, Nana F, Dingemans A, Aerts J, Ferrara R, Torri V, Abu Hejleh T, Takada K, Naqash A, Garassino M, Peters S, Wakelee H, Nassar A, Ricciuti B. Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. Journal For ImmunoTherapy Of Cancer 2025, 13: e010674. PMID: 39904562, PMCID: PMC11795382, DOI: 10.1136/jitc-2024-010674.
- Ayoade O, Canavan M, Zolfaghari E, Caturegli G, Kim S, Boffa D. Recent Survival Gains in Stage IV NSCLC by Sociodemographic Strata. JTO Clinical And Research Reports 2025, 6: 100798. PMID: 40212792, PMCID: PMC11985032, DOI: 10.1016/j.jtocrr.2025.100798.
- Nassar A, Kim S, Adib E, Naqash A, Goldberg S. Response to Letter to the Editor From Drs. Xiaowei Huang, Xian Gu, and Zhenye Xu. Journal Of Thoracic Oncology 2025, 20: e2-e3. PMID: 39794113, DOI: 10.1016/j.jtho.2024.10.011.
- Nassar A, Jayakrishnan R, Feng J, Shepherd F, Adib E, Cheung J, Lin J, Liu Y, Lin S, Parikh K, Sridhar A, Shakya P, Dilling T, Kaldas D, Gray J, Lobachov A, Bar J, Luders H, Grohe C, Gupta S, Leal T, Fitzgerald B, Crowley F, Fujiwara Y, Marron T, Wilgucki M, Reuss J, Chen L, Sankar K, Aredo J, Neal J, Wakelee H, Thummalapalli R, Yu H, Whitaker R, Velazquez A, Ragavan M, Cortellini A, Kwiatkowski D, Naqash A, Goldberg S, Kim S. Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC. Journal Of Thoracic Oncology 2024, 20: 109-118. PMID: 39260522, PMCID: PMC12874404, DOI: 10.1016/j.jtho.2024.09.1379.
- Fletcher K, Nassar A, Menzies A, Long G, Aboubakar Nana F, Malgeri A, Cortellini A, Shah S, Hassel J, Kim S, Naqash A, Challa P, Johnson D. Safety and efficacy of immune checkpoint inhibitors (ICI) in patients (pts) with pre-existing neurologic autoimmune diseases (NAID) and Parkinson's disease. Journal Of Clinical Oncology 2024, 42: 2653-2653. DOI: 10.1200/jco.2024.42.16_suppl.2653.
- Nassar A, Kim S, Adib E, Naqash A, Goldberg S. Response letter by Nassar et al. Journal Of Thoracic Oncology 2024, 19: e7-e8. PMID: 38719428, DOI: 10.1016/j.jtho.2024.03.013.
- Nassar A, El Zarif T, Khalid A, Rahme S, Zhong C, Kwak L, Salame M, Farhat E, Freeman D, El-Am E, Ravishankar A, Ahmad B, Nana F, Kaldas D, Naqash A, Sharon E, LeBoeuf N, Cortellini A, Malgeri A, Gupta S, Al-Hader A, Sparks J, Linnoila J, Hamnvik O, Mouhieddine T, Marron T, Parikh K, McKay R, Dilling T, Choueiri T, Adib E, Najem E, Kim S, Sonpavde G. Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes. Journal For ImmunoTherapy Of Cancer 2024, 12: e008724. PMID: 38448038, PMCID: PMC10916116, DOI: 10.1136/jitc-2023-008724.
- Nassar A, Kim S, Aredo J, Feng J, Shepherd F, Xu C, Kaldas D, Gray J, Dilling T, Neal J, Wakelee H, Liu Y, Lin S, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron T, Thummalapalli R, Yu H, Owen D, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris J, Nagasaka M, Ayanambakkam A, Velazquez A, Ragavan M, Lin J, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar S, Gupta S, Leal T, Kwiatkowski D, Mak R, Adib E, Naqash A, Goldberg S. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. Journal Of Thoracic Oncology 2024, 19: 928-940. PMID: 38278303, DOI: 10.1016/j.jtho.2024.01.012.
- Kim S, Gettinger S. First-Line Treatment of Driver-Negative Non–Small Cell Lung Cancer. Hematology/Oncology Clinics Of North America 2023, 37: 557-573. PMID: 37150586, DOI: 10.1016/j.hoc.2023.02.008.
- Negrao M, Araujo H, Lamberti G, Cooper A, Akhave N, Zhou T, Delasos L, Hicks J, Aldea M, Minuti G, Hines J, Aredo J, Dennis M, Chakrabarti T, Scott S, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess J, Kim S, Goldberg S, Li M, Wang Q, Qing Y, Ni Y, Truong M, Lee R, Ricciuti B, Alessi J, Wang J, Resuli B, Landi L, Tseng S, Nishino M, Digumarthy S, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan A, Blumenschein G, Zhang J, Owen D, Blakely C, Mountzios G, Shu C, Bestvina C, Garassino M, Marrone K, Gray J, Patel S, Cummings A, Wakelee H, Wolf J, Scagliotti G, Cappuzzo F, Barlesi F, Patil P, Drusbosky L, Gibbons D, Meric-Bernstam F, Lee J, Heymach J, Hong D, Heist R, Awad M, Skoulidis F. Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC. Cancer Discovery 2023, 13: 1556-1571. PMID: 37068173, PMCID: PMC11024958, DOI: 10.1158/2159-8290.cd-22-1420.
- Narvel H, Kim S, Shokrekhuda A, Cohen P, Ramesh K, Solomon S, Paik P, Halmos B. Orthogonal Testing Unravels a Novel ROS1 Oncogenic Fusion Variant (ROS1-GPM6A): A Practical Approach to Molecular Testing for Actionable Fusion Variants. JCO Precision Oncology 2023, 7: e2200593. PMID: 37027811, DOI: 10.1200/po.22.00593.
- Kim S, Costa D, Shibahara D, Kobayashi S, Halmos B. EGFR-Directed Therapy in Lung Cancer. 2023 DOI: 10.1017/9781009342285.
- Kim SY, Herbst RS. BFAST but be smart: bTMB remains an exploratory biomarker in NSCLC. Nature Reviews Clinical Oncology 2022, 20: 3-4. PMID: 36271141, DOI: 10.1038/s41571-022-00698-y.
- Kim SY, Yin J, Bohlman S, Walker P, Dacic S, Kim C, Khan H, Liu SV, C. P, Nagasaka M, Reckamp KL, Abraham J, Uprety D, Wang F, Xiu J, Zhang J, Cheng H, Halmos B. Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing. JTO Clinical And Research Reports 2022, 3: 100381. PMID: 36082279, PMCID: PMC9445394, DOI: 10.1016/j.jtocrr.2022.100381.
- Patel D, Maia C, Lyudmer M, Tolu S, Chergui A, Patel R, Kim S, Gali R, Villaorduna A, Goel S. Survival analysis of patients with early and standard onset colorectal cancer: A single center study. Journal Of Clinical Oncology 2022, 40: e15512-e15512. DOI: 10.1200/jco.2022.40.16_suppl.e15512.
- Kim S, Maitra R, Goel S. Multimodal immune activation abilities and characteristics of reovirus. American Journal Of Translational Research 2021, 13: 14176-14185. PMID: 35035763, PMCID: PMC8748157.
- Tariq S, Kim S, Monteiro de Oliveira Novaes J, Cheng H. Update 2021: Management of Small Cell Lung Cancer. Lung 2021, 199: 579-587. PMID: 34757446, DOI: 10.1007/s00408-021-00486-y.
- Thakkar A, Gonzalez-Lugo J, Goradia N, Gali R, Shapiro L, Pradhan K, Rahman S, Kim S, Ko B, Sica R, Kornblum N, Bachier-Rodriguez L, McCort M, Goel S, Perez-Soler R, Packer S, Sparano J, Gartrell B, Makower D, Goldstein Y, Wolgast L, Verma A, Halmos B. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell 2021, 39: 1081-1090.e2. PMID: 34133951, PMCID: PMC8179248, DOI: 10.1016/j.ccell.2021.06.002.
- Alexander M, Kim S, Cheng H. Update 2020: Management of Non-Small Cell Lung Cancer. Lung 2020, 198: 897-907. PMID: 33175991, PMCID: PMC7656891, DOI: 10.1007/s00408-020-00407-5.
- Kim S, Halmos B. Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver. Lung Cancer Management 2020, 9: lmt36. PMID: 32774467, PMCID: PMC7399613, DOI: 10.2217/lmt-2020-0003.
- Kim S, Wolfe D, Taub C. Cardiovascular outcomes of pregnancy in Marfan's syndrome patients: A literature review. Congenital Heart Disease 2017, 13: 203-209. PMID: 29063738, DOI: 10.1111/chd.12546.
- Kim S, Burns Z, Henry D. The assessment of thrombotic risk using a predictive model in metastatic cancer patients undergoing first-line therapy. Thrombosis Research 2012, 130: 967-970. PMID: 23036533, DOI: 10.1016/j.thromres.2012.09.008.
- Smilow Cancer Hospital Thoracic Oncology ProgramSmilow Cancer Hospital at North Haven6 Devine Street, Fl 2North Haven, CT 06473
- Smilow Cancer Hospital Phase I Unit55 Park StreetFl 1New Haven, CT 06511
Biography
So Yeon Kim, MD, is a medical oncologist who cares for patients with lung cancer, an area that she says is changing rapidly, thanks to new drugs in the past decade, targeted treatments, and immunotherapies that have led to significant improvements in outcomes even in people with advanced forms of the disease.
“I always knew I wanted to do something to help people,” Dr. Kim says. “I ultimately chose oncology because I enjoyed the long-term relationships I was able to build with patients and families. I really enjoy working with cancer patients because they are among the most resilient and courageous people, who continue to fight against a disease that still has many more problems to solve.”
Dr. Kim is working with colleagues toward personalizing cancer treatment for all patients with carefully selected treatment options based on the tumor’s “molecular fingerprint,” she says. “At Yale, there is a lot of ongoing scientific collaboration between clinicians and researchers that is helping bring the latest scientific discoveries to patients with the goal of improving their outcomes.”
An assistant professor at Yale School of Medicine, Dr. Kim focuses her research on both targeted treatment options and immunotherapy. “Oncology is a humbling field that can bring up more questions than answers, but I think that ultimately allows space for creativity and innovation,” she says. “While my research interests currently remain broad, I am interested in developing a more personalized approach to lung cancer care as we learn more about the science around what drives specific patients to respond better to certain therapies than to others,” she says.
Titles
- Assistant Professor
Education & Training
- MDAlbert Einstein College of Medicine (2016)
- ABPrinceton University (2011)
Additional Information
- ASCO Conquer Cancer Merit Award: ASCO (2022)
- Boiarsky D, Hong L, Ricciuti B, Cooper A, Saad M, Elkrief A, Di Federico A, Aminu M, Rinsurongkawong W, Le X, Luo J, Wu J, Gibbons D, Heymach J, Skoulidis F, Kim S, Schoenfeld A, Awad M, Zhang J, Vokes N. Disentangling KEAP1 and STK11 in KRAS-mutant (KRASm) non–small cell lung cancer (NSCLC) treated with immunotherapy. Journal Of Clinical Oncology 2026, 44: e20583-e20583. DOI: 10.1200/jco.2026.44.16_suppl.e20583.
- Boiarsky D, Hong L, Ricciuti B, Cooper A, Saad M, Elkrief A, Di Federico A, Aminu M, Rinsurongkawong W, Le X, Luo J, Wu J, Gibbons D, Heymach J, Skoulidis F, Kim S, Schoenfeld A, Awad M, Zhang J, Vokes N. Machine learning to identify biomarkers of response to immunotherapy in KRAS wildtype (KRASwt) non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2026, 44: e20609-e20609. DOI: 10.1200/jco.2026.44.16_suppl.e20609.
- Murciano-Goroff Y, Hollebecque A, Heist R, Cassier P, Han J, Kim S, Sabari J, Tosi D, Sacher A, Burns T, Shimizu T, Reddy Ammakkanavar N, Spira A, Gomez-Roca C, Patnaik A, Cosman R, Bodor J, Nagasaka M, You A, McNeely S, Peter R, Fink A, Chen A, Oxnard G, Willard M, Kuboki Y, Koyama T. Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study. Nature Communications 2026, 17: 3834. PMID: 41820335, PMCID: PMC13121619, DOI: 10.1038/s41467-026-69943-7.
- Gong G, Liu J, Pandya S, Taborda C, Wiesendanger N, Price N, Byron W, Coppi A, Young P, Wiess C, Dunning H, Barganier C, Brodeur R, Fischbach N, LoRusso P, Pusztai L, Kim S, Rozenblit M, Cecchini M, Mongiu A, Mendez L, Kaftan E, Torre C, Krumholz H, Krop I, Schulz W, Lustberg M, Kunz P. Clinical Trial Patient Matching: A Real-Time, Common Data Model and Artificial Intelligence–Driven System for Semiautomated Patient Prescreening in Cancer Clinical Trials. JCO Clinical Cancer Informatics 2026, 10: e2500262. PMID: 41512229, DOI: 10.1200/cci-25-00262.
- Cortellini A, Garbo E, La Cava G, Citarella F, Santo V, Brunetti L, Pinato D, Naidoo J, Loza M, Genova C, Gettinger S, Kim S, Jayakrishnan R, Zarif T, Russano M, Pecci F, Di Federico A, Montrone M, Owen D, Signorelli D, Li M, Camerini A, Halmos B, Vincenzi B, Metro G, Yendamuri S, Grossi F, Josephides E, Tomasik B, Giusti R, Bria E, Sebastian M, Rost M, Acker F, Landi L, Mazzoni F, Morabito A, Leonetti A, Cantini L, Mountzios G, Kalvapudi S, O'Reilly D, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Majem M, Piedra A, Cortinovis D, Tonini G, Minuti G, Mezquita L, Gorria T, Beninato T, Lo Russo G, PrelaJ A, De Giglio A, Biello F, Nana F, Dingemans A, Aerts J, Ferrara R, Abu Hejleh T, Takada K, Naqash A, Garassino M, Wakelee H, Nassar A, Ricciuti B, Soda P, Caruso C, Guarrasi V. Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity. Lung Cancer 2025, 209: 108799. PMID: 41108882, DOI: 10.1016/j.lungcan.2025.108799.
- Cortellini A, Santo V, Brunetti L, Garbo E, Pinato D, La Cava G, Naidoo J, Katz A, Loza M, Neal J, Genova C, Gettinger S, Kim S, Jayakrishnan R, Zarif T, Russano M, Pecci F, Di Federico A, Alessi J, Montrone M, Owen D, Ramella S, Signorelli D, Fidler M, Li M, Camerini A, Halmos B, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, D’Alessio A, Banna G, Fulgenzi C, Grisanti S, Grossi F, D’Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Balachandran K, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzoni F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Sforza V, Tiseo M, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Rocco D, Della Gravara L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O’Reilly D, Fitzpatrick O, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Piedra A, Agustoni F, Cortinovis D, Tonini G, Minuti G, Bennati C, Mezquita L, Gorría T, Servetto A, Beninato T, Russo G, Prelaj A, De Giglio A, Rogado J, Moliner L, Nadal E, Biello F, Nana F, Dingemans A, Aerts J, Ferrara R, Abu Hejleh T, Takada K, Naqash A, Garassino M, Peters S, Wakelee H, Nassar A, Ricciuti B, Soda P, Caruso C, Guarrasi V. Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry. Journal For ImmunoTherapy Of Cancer 2025, 13: e012423. PMID: 41022528, PMCID: PMC12481261, DOI: 10.1136/jitc-2025-012423.
- Kim S, Politi K, Goldberg S. Lasering in on Uncommon EGFR Mutations. Journal Of Thoracic Oncology 2025, 20: 1148-1151. PMID: 40914593, DOI: 10.1016/j.jtho.2025.06.014.
- Frisch A, Martin E, Kim S, Riess J, Sen T, Karim N. KRAS mutated NSCLC: past, present, and future directions in a rapidly evolving landscape. The Oncologist 2025, 30: oyaf153. PMID: 40586765, PMCID: PMC12207871, DOI: 10.1093/oncolo/oyaf153.
- Kim S, Park H, Chiang A. Small Cell Lung Cancer. JAMA: The Journal Of The American Medical Association 2025, 333: 1906-1917. PMID: 40163214, DOI: 10.1001/jama.2025.0560.
- Ayoade O, Canavan M, Zolfaghari E, Caturegli G, Kim S, Boffa D. Erratum to ‘Recent Survival Gains in Stage IV NSCLC by Sociodemographic Strata’ [JTO Clinical and Research Reports Volume 6 Issue 4 (2025) 100798]. JTO Clinical And Research Reports 2025, 6: 100850. PMID: 41473839, PMCID: PMC12745935, DOI: 10.1016/j.jtocrr.2025.100850.
- Fletcher K, Machaalani M, Chehade R, Nassar A, Nawfal R, Manos M, Menzies A, Aboubakar-Nana F, Hassel J, Pinato D, Johnson A, Olsson-Brown A, Carlino M, Malgeri A, Cortellini A, Singh A, Parikh K, Kim S, Naqash A, Long G, Challa P, Choueiri T, Sharon E, Shah S, Johnson D. Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic Disorders. JAMA Network Open 2025, 8: e2513727. PMID: 40465294, PMCID: PMC12138719, DOI: 10.1001/jamanetworkopen.2025.13727.
- Cortiula F, Kutiel T, Hsu M, Hendriks L, Nassar A, Moskovitz M, Kim S, Mirsky M, Jayakrishnan R, Bortolot M, Saddi J, Borghetti P, Chung M, Filippi A, De Ruysscher D, Bar J. Comparative efficacy of immunotherapy-based treatment versus chemotherapy-only in patients with unresectable NSCLC with disease progression post chemoradiation and durvalumab. European Journal Of Cancer 2025, 219: 115302. PMID: 39987799, DOI: 10.1016/j.ejca.2025.115302.
- Cortellini A, Brunetti L, Di Fazio G, Garbo E, Pinato D, Naidoo J, Katz A, Loza M, Neal J, Genova C, Gettinger S, Kim S, Jayakrishnan R, Zarif T, Russano M, Pecci F, Di Federico A, Awad M, Alessi J, Montrone M, Owen D, Signorelli D, Fidler M, Li M, Camerini A, De Giglio A, Young L, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, Awosika N, Napolitano A, Fulgenzi C, Grisanti S, Grossi F, D’Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Newsom-Davis T, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzoni F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Pantano F, Morabito A, Leonetti A, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Della Gravara L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O’Reilly D, Bell J, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Majem M, Agustoni F, Cortinovis D, Tonini G, Minuti G, Bennati C, Mezquita L, Gorría T, Servetto A, Beninato T, Russo G, Rogado J, Moliner L, Biello F, Nana F, Dingemans A, Aerts J, Ferrara R, Torri V, Abu Hejleh T, Takada K, Naqash A, Garassino M, Peters S, Wakelee H, Nassar A, Ricciuti B. Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. Journal For ImmunoTherapy Of Cancer 2025, 13: e010674. PMID: 39904562, PMCID: PMC11795382, DOI: 10.1136/jitc-2024-010674.
- Ayoade O, Canavan M, Zolfaghari E, Caturegli G, Kim S, Boffa D. Recent Survival Gains in Stage IV NSCLC by Sociodemographic Strata. JTO Clinical And Research Reports 2025, 6: 100798. PMID: 40212792, PMCID: PMC11985032, DOI: 10.1016/j.jtocrr.2025.100798.
- Nassar A, Kim S, Adib E, Naqash A, Goldberg S. Response to Letter to the Editor From Drs. Xiaowei Huang, Xian Gu, and Zhenye Xu. Journal Of Thoracic Oncology 2025, 20: e2-e3. PMID: 39794113, DOI: 10.1016/j.jtho.2024.10.011.
- Nassar A, Jayakrishnan R, Feng J, Shepherd F, Adib E, Cheung J, Lin J, Liu Y, Lin S, Parikh K, Sridhar A, Shakya P, Dilling T, Kaldas D, Gray J, Lobachov A, Bar J, Luders H, Grohe C, Gupta S, Leal T, Fitzgerald B, Crowley F, Fujiwara Y, Marron T, Wilgucki M, Reuss J, Chen L, Sankar K, Aredo J, Neal J, Wakelee H, Thummalapalli R, Yu H, Whitaker R, Velazquez A, Ragavan M, Cortellini A, Kwiatkowski D, Naqash A, Goldberg S, Kim S. Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC. Journal Of Thoracic Oncology 2024, 20: 109-118. PMID: 39260522, PMCID: PMC12874404, DOI: 10.1016/j.jtho.2024.09.1379.
- Fletcher K, Nassar A, Menzies A, Long G, Aboubakar Nana F, Malgeri A, Cortellini A, Shah S, Hassel J, Kim S, Naqash A, Challa P, Johnson D. Safety and efficacy of immune checkpoint inhibitors (ICI) in patients (pts) with pre-existing neurologic autoimmune diseases (NAID) and Parkinson's disease. Journal Of Clinical Oncology 2024, 42: 2653-2653. DOI: 10.1200/jco.2024.42.16_suppl.2653.
- Nassar A, Kim S, Adib E, Naqash A, Goldberg S. Response letter by Nassar et al. Journal Of Thoracic Oncology 2024, 19: e7-e8. PMID: 38719428, DOI: 10.1016/j.jtho.2024.03.013.
- Nassar A, El Zarif T, Khalid A, Rahme S, Zhong C, Kwak L, Salame M, Farhat E, Freeman D, El-Am E, Ravishankar A, Ahmad B, Nana F, Kaldas D, Naqash A, Sharon E, LeBoeuf N, Cortellini A, Malgeri A, Gupta S, Al-Hader A, Sparks J, Linnoila J, Hamnvik O, Mouhieddine T, Marron T, Parikh K, McKay R, Dilling T, Choueiri T, Adib E, Najem E, Kim S, Sonpavde G. Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes. Journal For ImmunoTherapy Of Cancer 2024, 12: e008724. PMID: 38448038, PMCID: PMC10916116, DOI: 10.1136/jitc-2023-008724.
- Nassar A, Kim S, Aredo J, Feng J, Shepherd F, Xu C, Kaldas D, Gray J, Dilling T, Neal J, Wakelee H, Liu Y, Lin S, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron T, Thummalapalli R, Yu H, Owen D, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris J, Nagasaka M, Ayanambakkam A, Velazquez A, Ragavan M, Lin J, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar S, Gupta S, Leal T, Kwiatkowski D, Mak R, Adib E, Naqash A, Goldberg S. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. Journal Of Thoracic Oncology 2024, 19: 928-940. PMID: 38278303, DOI: 10.1016/j.jtho.2024.01.012.
- Kim S, Gettinger S. First-Line Treatment of Driver-Negative Non–Small Cell Lung Cancer. Hematology/Oncology Clinics Of North America 2023, 37: 557-573. PMID: 37150586, DOI: 10.1016/j.hoc.2023.02.008.
- Negrao M, Araujo H, Lamberti G, Cooper A, Akhave N, Zhou T, Delasos L, Hicks J, Aldea M, Minuti G, Hines J, Aredo J, Dennis M, Chakrabarti T, Scott S, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess J, Kim S, Goldberg S, Li M, Wang Q, Qing Y, Ni Y, Truong M, Lee R, Ricciuti B, Alessi J, Wang J, Resuli B, Landi L, Tseng S, Nishino M, Digumarthy S, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan A, Blumenschein G, Zhang J, Owen D, Blakely C, Mountzios G, Shu C, Bestvina C, Garassino M, Marrone K, Gray J, Patel S, Cummings A, Wakelee H, Wolf J, Scagliotti G, Cappuzzo F, Barlesi F, Patil P, Drusbosky L, Gibbons D, Meric-Bernstam F, Lee J, Heymach J, Hong D, Heist R, Awad M, Skoulidis F. Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC. Cancer Discovery 2023, 13: 1556-1571. PMID: 37068173, PMCID: PMC11024958, DOI: 10.1158/2159-8290.cd-22-1420.
- Narvel H, Kim S, Shokrekhuda A, Cohen P, Ramesh K, Solomon S, Paik P, Halmos B. Orthogonal Testing Unravels a Novel ROS1 Oncogenic Fusion Variant (ROS1-GPM6A): A Practical Approach to Molecular Testing for Actionable Fusion Variants. JCO Precision Oncology 2023, 7: e2200593. PMID: 37027811, DOI: 10.1200/po.22.00593.
- Kim S, Costa D, Shibahara D, Kobayashi S, Halmos B. EGFR-Directed Therapy in Lung Cancer. 2023 DOI: 10.1017/9781009342285.
- Kim SY, Herbst RS. BFAST but be smart: bTMB remains an exploratory biomarker in NSCLC. Nature Reviews Clinical Oncology 2022, 20: 3-4. PMID: 36271141, DOI: 10.1038/s41571-022-00698-y.
- Kim SY, Yin J, Bohlman S, Walker P, Dacic S, Kim C, Khan H, Liu SV, C. P, Nagasaka M, Reckamp KL, Abraham J, Uprety D, Wang F, Xiu J, Zhang J, Cheng H, Halmos B. Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing. JTO Clinical And Research Reports 2022, 3: 100381. PMID: 36082279, PMCID: PMC9445394, DOI: 10.1016/j.jtocrr.2022.100381.
- Patel D, Maia C, Lyudmer M, Tolu S, Chergui A, Patel R, Kim S, Gali R, Villaorduna A, Goel S. Survival analysis of patients with early and standard onset colorectal cancer: A single center study. Journal Of Clinical Oncology 2022, 40: e15512-e15512. DOI: 10.1200/jco.2022.40.16_suppl.e15512.
- Kim S, Maitra R, Goel S. Multimodal immune activation abilities and characteristics of reovirus. American Journal Of Translational Research 2021, 13: 14176-14185. PMID: 35035763, PMCID: PMC8748157.
- Tariq S, Kim S, Monteiro de Oliveira Novaes J, Cheng H. Update 2021: Management of Small Cell Lung Cancer. Lung 2021, 199: 579-587. PMID: 34757446, DOI: 10.1007/s00408-021-00486-y.
- Thakkar A, Gonzalez-Lugo J, Goradia N, Gali R, Shapiro L, Pradhan K, Rahman S, Kim S, Ko B, Sica R, Kornblum N, Bachier-Rodriguez L, McCort M, Goel S, Perez-Soler R, Packer S, Sparano J, Gartrell B, Makower D, Goldstein Y, Wolgast L, Verma A, Halmos B. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell 2021, 39: 1081-1090.e2. PMID: 34133951, PMCID: PMC8179248, DOI: 10.1016/j.ccell.2021.06.002.
- Alexander M, Kim S, Cheng H. Update 2020: Management of Non-Small Cell Lung Cancer. Lung 2020, 198: 897-907. PMID: 33175991, PMCID: PMC7656891, DOI: 10.1007/s00408-020-00407-5.
- Kim S, Halmos B. Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver. Lung Cancer Management 2020, 9: lmt36. PMID: 32774467, PMCID: PMC7399613, DOI: 10.2217/lmt-2020-0003.
- Kim S, Wolfe D, Taub C. Cardiovascular outcomes of pregnancy in Marfan's syndrome patients: A literature review. Congenital Heart Disease 2017, 13: 203-209. PMID: 29063738, DOI: 10.1111/chd.12546.
- Kim S, Burns Z, Henry D. The assessment of thrombotic risk using a predictive model in metastatic cancer patients undergoing first-line therapy. Thrombosis Research 2012, 130: 967-970. PMID: 23036533, DOI: 10.1016/j.thromres.2012.09.008.
- Smilow Cancer Hospital Thoracic Oncology ProgramSmilow Cancer Hospital at North Haven6 Devine Street, Fl 2North Haven, CT 06473
- Smilow Cancer Hospital Phase I Unit55 Park StreetFl 1New Haven, CT 06511
- Smilow Cancer Hospital Thoracic Oncology ProgramSmilow Cancer Hospital at North Haven6 Devine Street, Fl 2North Haven, CT 06473
- Smilow Cancer Hospital Phase I Unit55 Park StreetFl 1New Haven, CT 06511